Overview
- The plan adds two facilities in Durham for biologics manufacturing and sterile packaging, plus a Morrisville site for tablet and capsule production with packaging.
- Novartis will expand its existing Durham campus to add aseptic filling of biologics into syringes and vials.
- The hub is slated to open in 2027–2028 with a combined footprint exceeding 700,000 square feet.
- The company projects about 700 new Novartis roles and more than 3,000 indirect supply-chain jobs by the end of 2030.
- The North Carolina hub advances a five-year, $23 billion U.S. manufacturing program that also sites cell and gene and radioligand production nationwide, with an RNA facility location to be announced.